1.0
Cite Score 2025
SJR: 0.129 / SNIP: 0.140
JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
Volume 18, Issue 2 (2026)
3 2026, 18(2): 129-140 |
Back to browse issues page
Request Type:
History
Received: 2026/01/6 | Accepted: 2026/03/2 | Published: 2026/03/28
Received: 2026/01/6 | Accepted: 2026/03/2 | Published: 2026/03/28
How to cite this article
Shahraki S, Bahador M, Alimohammadzadeh K, Begloo-Amin G, Mirzaei A. Factors Influencing Medication Adherence among Patients with Diabetes. 3 2026; 18 (2) :129-140
URL: http://ijwph.daneshafarand.org/article-3-85686-en.html
URL: http://ijwph.daneshafarand.org/article-3-85686-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Health Services Management, Te.M.S.C. (Tehran Medical Sciences Campus), Islamic Azad University, Tehran, Iran
2- Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- “Department of Health Services Management, N.T.C. (North Tehran Campus)” and “Health Economics Policy Research Center, Te.M.S.C. (Tehran Medical Sciences Campus)”, Islamic Azad University, Tehran, Iran
2- Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- “Department of Health Services Management, N.T.C. (North Tehran Campus)” and “Health Economics Policy Research Center, Te.M.S.C. (Tehran Medical Sciences Campus)”, Islamic Azad University, Tehran, Iran
Abstract (162 Views)
Aims: This scoping review aimed to identify and synthesize the key factors influencing medication adherence among patients with diabetes.
Information & Methods: This scoping review was conducted following the Arksey & O’Malley framework. The review scope was defined using the population, concept, and context approach, including patients with all types of diabetes, the concept of medication adherence, and all healthcare delivery settings. A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and SID was performed for Persian- and English-language articles published between 2003 and 2025. Study screening was conducted using the Rayyan platform. In total, 52 eligible studies were included. Data were analyzed through narrative synthesis and inductive content analysis, and the results were reported in accordance with the PRISMA-ScR guideline.
Findings: Individual and demographic, psychological and behavioral, treatment-related, economic and access-related, and systemic factors influenced medication adherence among patients with diabetes. These factors encompassed a wide range of patient characteristics, treatment attributes, economic and access constraints, and components related to supportive interactions and healthcare system performance.
Conclusion: Medication adherence among patients with diabetes is a multilevel phenomenon shaped by interactions among individual, psychological, treatment-related, economic, and systemic factors.
Information & Methods: This scoping review was conducted following the Arksey & O’Malley framework. The review scope was defined using the population, concept, and context approach, including patients with all types of diabetes, the concept of medication adherence, and all healthcare delivery settings. A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and SID was performed for Persian- and English-language articles published between 2003 and 2025. Study screening was conducted using the Rayyan platform. In total, 52 eligible studies were included. Data were analyzed through narrative synthesis and inductive content analysis, and the results were reported in accordance with the PRISMA-ScR guideline.
Findings: Individual and demographic, psychological and behavioral, treatment-related, economic and access-related, and systemic factors influenced medication adherence among patients with diabetes. These factors encompassed a wide range of patient characteristics, treatment attributes, economic and access constraints, and components related to supportive interactions and healthcare system performance.
Conclusion: Medication adherence among patients with diabetes is a multilevel phenomenon shaped by interactions among individual, psychological, treatment-related, economic, and systemic factors.
Keywords:
References
1. Duncan BB, Magliano DJ, Boyko EJ. IDF diabetes atlas 11th edition 2025: Global prevalence and projections for 2050. Nephrol Dial Transplant. 2025;41(1):7-9. [Link] [DOI:10.1093/ndt/gfaf177]
2. Ogle GD, Wang F, Haynes A, Gregory GA, King TW, Deng K, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract. 2025;225:112277. [Link] [DOI:10.1016/j.diabres.2025.112277]
3. Noubiap JJ, Nansseu JR, Nyaga UF, Ndoadoumgue AL, Ngouo AT, Tounouga DN, et al. Worldwide trends in metabolic syndrome from 2000 to 2023: A systematic review and modelling analysis. Nat Commun. 2025;17(1):573. [Link] [DOI:10.1038/s41467-025-67268-5]
4. Giorgino F, Alzaid F, Pantea Stoian A, Chan JC, Ji L, Lumu W, et al. Global challenges in diabetes research and care: Which way forward? An appraisal from the EASD Global Council. Diabetologia. 2025;68(11):2479-98. [Link] [DOI:10.1007/s00125-025-06504-5]
5. Kunutsor SK, Balasubramanian VG, Zaccardi F, Gillies CL, Aroda VR, Seidu S, et al. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta‐analysis of trials investigating intensive glucose‐lowering strategies in people with type 2 diabetes. Diabetes Obes Metab. 2024;26(6):2069-81. [Link] [DOI:10.1111/dom.15511]
6. Al-Salmi N, Muliira JK, Lazarus ER. Medication adherence in adults with type 2 diabetes: A comprehensive qualitative meta-synthesis of factors in the MENA Region. Patient Prefer Adherence. 2025;19:2263-81. [Link] [DOI:10.2147/PPA.S526844]
7. Mann DM, Ponieman D, Leventhal H, Halm EA. Predictors of adherence to diabetes medications: The role of disease and medication beliefs. J Behav Med. 2009;32(3):278-84. [Link] [DOI:10.1007/s10865-009-9202-y]
8. Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann‐Boyce J, Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS‐CoV‐2: A systematic review and meta‐analysis. Endocrinol Diabetes Metab. 2020;4(1):e00176. [Link] [DOI:10.1002/edm2.176]
9. Highton PJ, Funnell MP, Gupta P, Zaccardi F, Lim LL, Seidu S, et al. Improving medication adherence in type 2 diabetes: Strategies for better clinical and economic outcomes. Diabetologia. 2026;69(3):541-56. [Link] [DOI:10.1007/s00125-025-06617-x]
10. Dunbar-Jacob J, Zhao J. Medication adherence measurement in chronic diseases: A state-of-the-art review of the literature. Nurs Rep. 2025;15(10):370. [Link] [DOI:10.3390/nursrep15100370]
11. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: A systematic review. BMJ Open. 2018;8(1):e016982. [Link] [DOI:10.1136/bmjopen-2017-016982]
12. Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clin Proc. 2011;86(4):304-14. [Link] [DOI:10.4065/mcp.2010.0575]
13. Vatan Meidanshahi A, Alaei-Shahmiri F, Golgiri F, Mavvaji MA, Dinko B, Shahi R, et al. Assessing the association between anti-diabetic medication adherence and glycemic control in type 2 diabetes. Iran J Diabetes Obes. 2025;17(2):79-87. [Link] [DOI:10.18502/ijdo.v17i2.18846]
14. Shrivastava SR, Shrivastava PS, Ramasamy J. Role of self-care in management of diabetes mellitus. J Diabetes Metab Disord. 2013;12(1):14. [Link] [DOI:10.1186/2251-6581-12-14]
15. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: A review of systematic reviews. Front Pharmacol. 2013;4:91. [Link] [DOI:10.3389/fphar.2013.00091]
16. Alqarni AM, Alrahbeni T, Qarni AA, Qarni HMA. Adherence to diabetes medication among diabetic patients in the Bisha governorate of Saudi Arabia-a cross-sectional survey. Patient Prefer Adherence. 2018;13:63-71. [Link] [DOI:10.2147/PPA.S176355]
17. Alnajjar JS, Alwosaibei AA, Alameen MA, Alqadeep AF, Alanazi R, Alnajim AH, et al. Factors influencing adherence to refills and medications in patients with type 2 diabetes mellitus in Saudi Arabia: A questionnaire-based study. Diabetes Metab Syndr Obes. 2025;18:2289-304. [Link] [DOI:10.2147/DMSO.S505605]
18. Morrison AK, Glick A, Yin HS. Health literacy: Implications for child health. Pediatr Rev. 2019;40(6):263-77. [Link] [DOI:10.1542/pir.2018-0027]
19. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-41. [Link] [DOI:10.1001/archinte.166.17.1836]
20. Gotfredsen DR, Vinther S, Petersen TS, Cortes R, Jensen TB, Jimenez-Solem E, et al. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years. Sci Rep. 2020;10(1):4095. [Link] [DOI:10.1038/s41598-020-60818-5]
21. Fusco N, Sils B, Graff JS, Kistler K, Ruiz K. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review. J Manag Care Spec Pharm. 2023;29(1):4-16. [Link] [DOI:10.18553/jmcp.2022.21270]
22. Georgieva N, Tenev V, Kamusheva M, Petrova G. Diabetes mellitus-digital solutions to improve medication adherence: Scoping review. Diabetology. 2023;4(4):465-80. [Link] [DOI:10.3390/diabetology4040040]
23. Levac D, Colquhoun H, O'brien KK. Scoping studies: Advancing the methodology. Implement Sci. 2010;5(1):69. [Link] [DOI:10.1186/1748-5908-5-69]
24. Arksey H, O'malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19-32. [Link] [DOI:10.1080/1364557032000119616]
25. Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141-6. [Link] [DOI:10.1097/XEB.0000000000000050]
26. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. [Link] [DOI:10.1186/s13643-016-0384-4]
27. Munn Z, Peters MD, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143. [Link] [DOI:10.1186/s12874-018-0611-x]
28. Peters MD, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119-26. [Link] [DOI:10.11124/JBIES-20-00167]
29. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC methods programme. Lancaster: Lancaster University; 2006. [Link]
30. Braun V, Clarke V. Thematic analysis: A practical guide. Washington DC: SAGE Publications; 2021. [Link]
31. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467-73. [Link] [DOI:10.7326/M18-0850]
32. Fendrick AM, Buxbaum JD, Tang Y, Vlahiotis A, McMorrow D, Rajpathak S, et al. Association between switching to a high-deductible health plan and discontinuation of type 2 diabetes treatment. JAMA Netw Open. 2019;2(11):e1914372. [Link] [DOI:10.1001/jamanetworkopen.2019.14372]
33. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and the use of generic drug therapies. Am J Manag Care. 2009;15(7):450-6. [Link]
34. Spaans EA, Kleefstra N, Groenier KH, Bilo HJ, Brand PL. Adherence to insulin pump treatment declines with increasing age in adolescents with type 1 diabetes mellitus. Acta Paediatr. 2020;109(1):134-9. [Link] [DOI:10.1111/apa.14931]
35. Dankers M, van den Berk-Bulsink MJE, van Dalfsen-Slingerland M, Nelissen-Vrancken HJMG, Mantel-Teeuwisse AK, van Dijk L. Non-adherence to guideline recommendations for insulins: a qualitative study amongst primary care practitioners. BMC Prim Care. 2022;23(1):150. [Link] [DOI:10.1186/s12875-022-01760-5]
36. Gao Q, Peng L, Min W, Nie J, Wang A, Shi Y, et al. Regularity of clinical visits and medication adherence of patients with hypertension or diabetes in rural Yunnan province of China. Int J Environ Res Public Health. 2020;17(24):9297. [Link] [DOI:10.3390/ijerph17249297]
37. Pednekar PP, Agh T, Malmenäs M, Raval AD, Bennett BM, Borah BJ, et al. Methods for measuring multiple medication adherence: A systematic review-report of the ISPOR medication adherence and persistence special interest group. Value Health. 2019;22(2):139-56. [Link] [DOI:10.1016/j.jval.2018.08.006]
38. Jensen ML, Jørgensen ME, Hansen EH, Aagaard L, Carstensen B. Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: The importance of initiation. PLoS One. 2017;12(6):e0179546. [Link] [DOI:10.1371/journal.pone.0179546]
39. Mantila KM, Pasmooij AM, Hallgreen CE, Mol PG, Van Boven JF. Medication adherence measurement methods in registration trials supporting the approval of new medicines: A cross‐sectional analysis of centralized procedures in the European :union: 2010-2020. Clin Pharmacol Ther. 2022;112(5):1051-60. [Link] [DOI:10.1002/cpt.2709]
40. Karter AJ, Parker MM, Solomon MD, Lyles CR, Adams AS, Moffet HH, et al. Effect of out‐of‐pocket cost on medication initiation, adherence, and persistence among patients with type 2 diabetes: The diabetes study of northern California (DISTANCE). Health Serv Res. 2018;53(2):1227-47. [Link] [DOI:10.1111/1475-6773.12700]
41. Murwanashyaka JDD, Ndagijimana A, Biracyaza E, Sunday FX, Umugwaneza M. Non-adherence to medication and associated factors among type 2 diabetes patients at Clinique Medicale Fraternite, Rwanda: A cross-sectional study. BMC Endocr Disord. 2022;22(1):219. [Link] [DOI:10.1186/s12902-022-01133-0]
42. Zairina E, Nugraheni G, Sulistyarini A, Mufarrihah, Setiawan CD, Kripalani S, et al. Factors related to barriers and medication adherence in patients with type 2 diabetes mellitus: a cross-sectional study. J Diabetes Metab Disord. 2022;21(1):219-28. [Link] [DOI:10.1007/s40200-021-00961-6]
43. Sahoo J, Mohanty S, Kundu A, Epari V. Medication adherence among patients of type II diabetes mellitus and its associated risk factors: A cross-sectional study in a tertiary care hospital of eastern India. Cureus. 2022;14(12):e33074. [Link] [DOI:10.7759/cureus.33074]
44. Asheq A, Ashames A, Al-Tabakha M, Hassan N, Jairoun A. Medication adherence in type 2 diabetes mellitus patients during Covid-19 pandemic: A cross-sectional study from the United Arab Emirates. F1000Res. 2021;10:435. [Link] [DOI:10.12688/f1000research.51729.2]
45. AlShayban DM, Naqvi AA, Alhumaid O, AlQahtani AS, Islam MA, Ghori SA, et al. Association of disease knowledge and medication adherence among out-patients with type 2 diabetes mellitus in Khobar, Saudi Arabia. Front Pharmacol. 2020;11:60. [Link] [DOI:10.3389/fphar.2020.00060]
46. Huang J, Ding S, Xiong S, Liu Z. Medication adherence and associated factors in patients with type 2 diabetes: A structural equation model. Front Public Health. 2021;9:730845. [Link] [DOI:10.3389/fpubh.2021.730845]
47. Xu N, Xie S, Chen Y, Li J, Sun L. Factors influencing medication non-adherence among Chinese older adults with diabetes mellitus. Int J Environ Res Public Health. 2020;17(17):6012. [Link] [DOI:10.3390/ijerph17176012]
48. Muhammad Haskani NH, Goh HP, Wee DVT, Hermansyah A, Goh KW, Ming LC. Medication knowledge and adherence in type 2 diabetes mellitus patients in Brunei Darussalam: A pioneer study in Brunei Darussalam. Int J Environ Res Public Health. 2022;19(12):7470. [Link] [DOI:10.3390/ijerph19127470]
49. Teng CL, Chan CW, Wong PS. Medication adherence of persons with type 2 diabetes in Malaysia: A scoping review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37(1):75-82. [Link] [DOI:10.15605/jafes.037.01.14]
50. Pourhabibi N, Mohebbi B, Sadeghi R, Shakibazadeh E, Sanjari M, Tol A, et al. Determinants of poor treatment adherence among patients with type 2 diabetes and limited health literacy: A scoping review. J Diabetes Res. 2022;2022:2980250. [Link] [DOI:10.1155/2022/2980250]
51. Munshi KD, Amelung K, Carter CS, James R, Shah BR, Henderson RR. Impact of a diabetes remote monitoring program on medication adherence. J Manag Care Spec Pharm. 2021;27(6):724-31. [Link] [DOI:10.18553/jmcp.2021.27.6.724]
52. Bilondi SS, Noghabi AD, Aalami H. The relationship between illness perception and medication adherence in patients with diabetes mellitus type II: Illness perception and medication adherence. J Prev Med Hyg. 2022;62(4):E966-71. [Link] [DOI:10.21203/rs.3.rs-426152/v1]
53. Kwakye AO, Kretchy IA, Peprah P, Mensah KB. Factors influencing medication adherence in co-morbid hypertension and diabetes patients: A scoping review. Explor Res Clin Soc Pharm. 2024;13:100426. [Link] [DOI:10.1016/j.rcsop.2024.100426]
54. Alsaidan AA, Alotaibi SF, Thirunavukkarasu A, ALruwaili BF, Alharbi RH, Arnous MM, et al. Medication adherence and its associated factors among patients with type 2 diabetes mellitus attending primary health centers of Eastern Province, Saudi Arabia. Medicina. 2023;59(5):989. [Link] [DOI:10.3390/medicina59050989]
55. Dinkova R, Marinov L, Doneva M, Kamusheva M. Medication adherence among patients with diabetes mellitus and its related factors-a real-world pilot study in Bulgaria. Medicina. 2023;59(7):1205. [Link] [DOI:10.3390/medicina59071205]
56. Nelson LA, Wallston KA, Kripalani S, LeStourgeon LM, Williamson SE, Mayberry LS. Assessing barriers to diabetes medication adherence using the Information-Motivation-Behavioral skills model. Diabetes Res Clin Pract. 2018;142:374-84. [Link] [DOI:10.1016/j.diabres.2018.05.046]
57. Sendekie AK, Netere AK, Kasahun AE, Belachew EA. Medication adherence and its impact on glycemic control in type 2 diabetes mellitus patients with comorbidity: A multicenter cross-sectional study in Northwest Ethiopia. PLoS One. 2022;17(9):e0274971. [Link] [DOI:10.1371/journal.pone.0274971]
58. Mishra R, Sharma SK, Verma R, Kangra P, Dahiya P, Kumari P, et al. Medication adherence and quality of life among type-2 diabetes mellitus patients in India. World J Diabetes. 2021;12(10):1740-9. [Link] [DOI:10.4239/wjd.v12.i10.1740]
59. Yosef T, Nureye D, Tekalign E, Assefa E, Shifera N. Medication adherence and contributing factors among type 2 diabetes patients at Adama Hospital Medical College in Eastern Ethiopia. SAGE Open Nurs. 2023;9:23779608231158975. [Link] [DOI:10.1177/23779608231158975]
60. Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151-73. [Link] [DOI:10.1108/S0731-2199(2010)0000022010]
61. Gow K, Rashidi A, Whithead L. Factors influencing medication adherence among adults living with diabetes and comorbidities: A qualitative systematic review. Curr Diab Rep. 2024;24(2):19-25. [Link] [DOI:10.1007/s11892-023-01532-0]
62. Huang YM, Pecanac KE, Shiyanbola OO. "Why am I not taking medications?" Barriers and facilitators of diabetes medication adherence across different health literacy levels. Qual Health Res. 2020;30(14):2331-42. [Link] [DOI:10.1177/1049732320945296]
63. Świątoniowska-Lonc N, Tański W, Polański J, Jankowska-Polańska B, Mazur G. Psychosocial determinants of treatment adherence in patients with type 2 diabetes-a review. Diabetes Metab Syndr Obes. 2021;14:2701-15. [Link] [DOI:10.2147/DMSO.S308322]
64. Eshete A, Getye B, Aynaddis G, Tilaye B, Mekonnen E, Taye B, et al. Association between illness perception and medication adherence in patients with diabetes mellitus in North Shoa, Zone: Cross-sectional study. Front Public Health. 2023;11:1214725. [Link] [DOI:10.3389/fpubh.2023.1214725]
65. Calderon C, Carrete L, Vera-Martínez J, Gloria-Quintero ME, Romero-Figueroa MdS. A social marketing intervention to improve treatment adherence in patients with type 1 diabetes. Int J Environ Res Public Health. 2021;18(7):3622. [Link] [DOI:10.3390/ijerph18073622]
66. Colombo GL, Agabiti-Rosei E, Margonato A, Mencacci C, Montecucco CM, Trevisan R, et al. Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 local healthcare units in the Lombardy region of Italy. Atheroscler Suppl. 2016;21:1-8. [Link] [DOI:10.1016/j.atherosclerosissup.2016.02.001]
67. Azar S, Maroun Abou Jaoude N, Kędzia A, Niechciał E. Barriers to type 1 diabetes adherence in adolescents. J Clin Med. 2024;13(19):5669. [Link] [DOI:10.3390/jcm13195669]
68. Athavale AS, Bentley JP, Banahan III BF, McCaffrey III DJ, Pace PF, Vorhies DW. Development of the medication adherence estimation and differentiation scale (MEDS). Curr Med Res Opin. 2019;35(4):577-85. [Link] [DOI:10.1080/03007995.2018.1512478]
69. Holdt‐Caspersen NS, Dethlefsen C, Vestergaard P, Hejlesen O, Hangaard S, Jensen MH. Adherence to newer second‐line oral antidiabetic drugs among people with type 2 diabetes-A systematic review. Pharmacol Res Perspect. 2024;12(2):e1185. [Link] [DOI:10.1002/prp2.1185]
70. Choudhry NK, Denberg TD, Qaseem A, Clinical Guidelines Committee of American College of Physicians. Improving adherence to therapy and clinical outcomes while containing costs: Opportunities from the greater use of generic medications: Best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016;164(1):41-9. [Link] [DOI:10.7326/M14-2427]
71. Yu M, Xie J, Lando LF, Kabul S, Swindle RW. Liraglutide versus exenatide once weekly: Persistence, adherence, and early discontinuation. Clin Ther. 2016;38(1):149-60. [Link] [DOI:10.1016/j.clinthera.2015.11.017]
72. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-7. [Link] [DOI:10.1001/archinte.166.3.332]
73. Al-Qerem W, Jarab AS, Badinjki M, Hyassat D, Qarqaz R. Exploring variables associated with medication non-adherence in patients with type 2 diabetes mellitus. PLoS One. 2021;16(8):e0256666. [Link] [DOI:10.1371/journal.pone.0256666]
74. Sapkota S, Brien JA, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes-impact on adherence. PLoS One. 2015;10(2):e0118296. [Link] [DOI:10.1371/journal.pone.0118296]
75. Warraich HJ, Siddiqi HK, Li DG, Van Meijgaard J, Vaduganathan M. Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States. PLoS One. 2023;18(12):e0294164. [Link] [DOI:10.1371/journal.pone.0294164]
76. Wang Y, Kang SY, Socal MP, Dusetzina SB. Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes. J Manag Care Spec Pharm. 2024;30(9):903-7. [Link] [DOI:10.18553/jmcp.2024.30.9.903]
77. Sacks NC, Burgess Jr JF, Cabral HJ, Pizer SD, McDonnell ME. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med. 2013;28(7):876-85. [Link] [DOI:10.1007/s11606-013-2342-3]
78. Sensharma A, Yabroff KR. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):263-77. [Link] [DOI:10.1080/14737167.2019.1567335]
79. Huang CX, Turk N, Ettner SL, Mangione CM, Moin T, O'Shea D, et al. Does the diabetes health plan have a differential impact on medication adherence among beneficiaries with fewer financial resources?. J Manag Care Spec Pharm. 2022;28(9):948-57. [Link] [DOI:10.18553/jmcp.2022.28.9.948]
80. Epstein LH, Paluch RA, Stein JS, Quattrin T, Mastrandrea LD, Bree KA, et al. Delay discounting, glycemic regulation and health behaviors in adults with prediabetes. Behav Med. 2021;47(3):194-204. [Link] [DOI:10.1080/08964289.2020.1712581]
81. Tajik A, Varmaghani M, Ghavami V, Saeedi N, Sharifi F, Khajavi A, et al. Availability and affordability of antidiabetic medicines in Herat of Afghanistan in 2023. J Diabetes Metab Disord. 2024;23(2):1929-40. [Link] [DOI:10.1007/s40200-024-01444-0]
82. Kong E, Beshears J, Laibson D, Madrian B, Volpp K, Loewenstein G, et al. Do physician incentives increase patient medication adherence?. Health Serv Res. 2020;55(4):503-11. [Link] [DOI:10.1111/1475-6773.13322]
83. AlBurno H, Mercken L, De Vries H, Al Mohannadi D, Jongen S, Schneider F. Socio-cognitive determinants affecting insulin adherence/non-adherence in late adolescents and young adults with type 1 diabetes: A systematic review protocol. J Diabetes Metab Disord. 2022;21(1):1207-15. [Link] [DOI:10.1007/s40200-022-01054-8]
84. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. [Link] [DOI:10.1002/14651858.CD000011.pub4]
85. Kini V, Ho PM. Interventions to improve medication adherence: A review. JAMA. 2018;320(23):2461-73. [Link] [DOI:10.1001/jama.2018.19271]
86. Woodward A, Walters K, Davies N, Nimmons D, Protheroe J, Chew‐Graham CA, et al. Barriers and facilitators of self‐management of diabetes amongst people experiencing socioeconomic deprivation: A systematic review and qualitative synthesis. Health Expect. 2024;27(3):e14070. [Link] [DOI:10.1111/hex.14070]
87. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: A meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633. [Link] [DOI:10.1371/journal.pone.0080633]
88. Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, et al. Medication adherence: A call for action. Am Heart J. 2011;162(3):412-24. [Link] [DOI:10.1016/j.ahj.2011.06.007]
89. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, et al. Variations in patients' perceptions and use of generic drugs: Results of a national survey. J Gen Intern Med. 2016;31(6):609-14. [Link] [DOI:10.1007/s11606-016-3612-7]
90. Håkonsen H, Toverud EL. A review of patient perspectives on generics substitution: What are the challenges for optimal drug use. Generics Biosimilars Initiat J. 2012;1(1):28-32. [Link] [DOI:10.5639/gabij.2012.0101.008]
91. Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14(1):1. [Link] [DOI:10.1186/2050-6511-14-1]
92. Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: A systematic review. BMJ Open. 2015;5(12):e008915. [Link] [DOI:10.1136/bmjopen-2015-008915]
93. Gonzalez JS, Tanenbaum ML, Commissariat PV. Psychosocial factors in medication adherence and diabetes self-management: Implications for research and practice. Am Psychol. 2016;71(7):539-51. [Link] [DOI:10.1037/a0040388]
94. Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients' lived experience with medicine: A systematic review and metasynthesis of qualitative studies. BMJ Open. 2016;6(2):e010035. [Link] [DOI:10.1136/bmjopen-2015-010035]
95. González-Saldivar G, Millan-Alanis JM, González-González JG, Sánchez-Gómez RA, Obeso-Fernández J, McCoy RG, et al. Treatment burden and perceptions of glucose-lowering therapy among people living with diabetes. Prim Care Diabetes. 2022;16(4):568-73. [Link] [DOI:10.1016/j.pcd.2022.04.002]
96. Chan AHY, Cooper V, Lycett H, Horne R. Practical barriers to medication adherence: What do current self-or observer-reported instruments assess?. Front Pharmacol. 2020;11:572. [Link] [DOI:10.3389/fphar.2020.00572]
97. Sarpatwari A, Gagne JJ, Lu Z, Campbell EG, Carman WJ, Enger CL, et al. A survey of patients' perceptions of pill appearance and responses to changes in appearance for four chronic disease medications. J Gen Intern Med. 2019;34(3):420-8. [Link] [DOI:10.1007/s11606-018-4791-1]
98. Studer CM, Linder M, Pazzagli L. A global systematic overview of socioeconomic factors associated with antidiabetic medication adherence in individuals with type 2 diabetes. J Health Popul Nutr. 2023;42(1):122. [Link] [DOI:10.1186/s41043-023-00459-2]
99. Barthold D, Li J, Basu A. Patient out-of-pocket costs for type 2 diabetes medications when aging into Medicare. JAMA Netw Open. 2024;7(7):e2420724. [Link] [DOI:10.1001/jamanetworkopen.2024.20724]
100. Karami MA, Hayati H. Investigating the socio-economic factors affecting affordability and availability of medications for patients with diabetes. J Hosp. 2023;22(3):250-61. [Persian] [Link]
101. Khalili Azar K, Mirzaei A, Babapour AR, Fathnezhad-Kazemi A. The mediating effect of self-efficacy on the relationship between social support and medication adherence in adults with type 2 diabetes. SAGE Open Med. 2024;12:20503121231221446. [Link] [DOI:10.1177/20503121231221446]
102. Erdoğan Yüce G, Yıldırım H. Mediating role of disease acceptance in the relationship between social support and adherence to treatment in patients with type 2 diabetes. J Behav Med. 2025;48(4):572-82. [Link] [DOI:10.1007/s10865-025-00567-w]
103. Angadi N, Shubha D. Social support and medication adherence among people with type 2 diabetes mellitus in central Karnataka, India. Natl J Community Med. 2023;14(12):834-41. [Link] [DOI:10.55489/njcm.141220233301]
104. Wang M, Lee K, Thew HZ, Sowtali SN, Jiang Q, Cao Y, et al. Medication adherence interventions among people living with diabetes: A systematic review. Patient Prefer Adherence. 2025;19:3095-112. [Link] [DOI:10.2147/PPA.S544443]